Ocular Therapeutix CEO to Lead March Investor Conferences Amid Key Clinical Trials
Event summary
- Ocular Therapeutix CEO Pravin U. Dugel to present at five investor conferences in March 2026.
- Fireside chats scheduled for TD Cowen, Citizens Life Sciences, and RBC Capital Markets conferences.
- AXPAXLI (OTX-TKI) in Phase 3 trials for wet AMD and diabetic retinal disease.
- DEXTENZA commercial product approved for ocular inflammation and pain post-surgery.
- OTX-TIC program for glaucoma/hypertension under evaluation for next steps.
The big picture
Ocular Therapeutix's participation in multiple investor conferences comes as it advances its lead candidate AXPAXLI through Phase 3 trials for wet AMD and diabetic retinal disease. The company's strategy hinges on its ELUTYX hydrogel technology, which also underpins its commercial product DEXTENZA and the OTX-TIC program for glaucoma. The upcoming presentations will be closely watched for updates on clinical progress and pipeline strategy in a competitive ophthalmology market.
What we're watching
- Clinical Trial Momentum
- The pace at which AXPAXLI advances through Phase 3 trials will determine Ocular Therapeutix's near-term valuation.
- Pipeline Strategy
- Whether Ocular Therapeutix can sustain momentum in its ELUTYX technology pipeline beyond AXPAXLI.
- Investor Sentiment
- How investor conferences will shape market perception of Ocular Therapeutix's retinal disease focus.